View Older Stories View More Recent Stories

Jun 21, 2022 04:14PM Form 4 Nuvalent, Inc. For: Jun 16 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Jun 2, 2022 04:04PM Form SC 13D/A CareMax, Inc. Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Jun 2, 2022 09:36AM EPIC SCIENCES RAISES $43M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
Jun 1, 2022 10:28AM EPIC SCIENCES RAISES $42M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
May 25, 2022 10:00AM Adela Initiates Key Study for Cancer Early Detection Program
May 23, 2022 10:00AM Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board
May 23, 2022 06:02AM Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
May 18, 2022 09:02AM Biotech Acquisition (BIOT) and Blade Report Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat
May 18, 2022 09:01AM Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 18, 2022 08:39AM Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs
May 17, 2022 07:00AM Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry
May 16, 2022 05:11PM Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
May 16, 2022 04:05PM Lumos Pharma to Participate in Upcoming Investor Conferences
May 16, 2022 04:05PM Lumos Pharma to Participate in Upcoming Investor Conferences
May 16, 2022 09:02AM Blade Therapeutics (BIOT) Reports Data from Phase 1 and Preclinical Studies of Cudetaxestat
May 16, 2022 09:01AM Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 16, 2022 07:30AM Miravo Healthcare™ Announces First Quarter 2022 Results
May 11, 2022 05:43PM Form 4 Larimar Therapeutics, For: May 10 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
May 10, 2022 04:01PM Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
May 10, 2022 04:01PM Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
May 10, 2022 05:40AM Biotech Acquisition (BIOT) and Blade Therapeutics Announce Effectiveness of Registration Statement, Signs $75M Committed Equity Financing
May 9, 2022 06:10PM Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combinat
May 5, 2022 08:01PM Form 3 PepGen Inc. For: May 05 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
May 5, 2022 04:05PM Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
May 5, 2022 09:15AM Illumina (ILMN) Partners with Deerfield Management to Accelerate Drug Development
May 5, 2022 09:15AM Illumina and Deerfield Management partner to accelerate drug development
May 5, 2022 09:01AM Lumos Pharma, Inc. (LUMO) Enters Collaboration with Massachusetts General Hospital to Evaluate LUM-201
May 5, 2022 09:00AM Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
May 5, 2022 09:00AM Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
May 4, 2022 07:00AM Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Apr 27, 2022 09:07AM Pre-Open Stock Movers 04/27: Mattel Up on Takeover Talk, Microsoft and Visa Gain on Earnings; NCR, Boeing, Google Drop Post Earnings (more...)
Apr 27, 2022 06:33AM Acutus Medical (AFIB) Announces Debt Refinancing, Left-Heart Access Portfolio Sale
Apr 27, 2022 06:30AM Acutus Medical Announces Agreements to Fund Strategic Growth Priorities
Apr 26, 2022 09:00AM Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
Apr 26, 2022 09:00AM Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
Apr 26, 2022 06:00AM Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines
Apr 26, 2022 05:43AM Valneva SE (VALN) Enters Upsized $40M Financing Arrangement with Deerfield and OrbiMed
Apr 26, 2022 01:28AM Vaccines company Valneva secures new financing with U.S firms Deerfield and OrbiMed
Apr 26, 2022 01:00AM Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
Apr 26, 2022 01:00AM Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
Apr 12, 2022 05:00AM Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures
Apr 11, 2022 08:30AM Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
Apr 11, 2022 08:30AM Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
Apr 8, 2022 01:01PM Dracen Pharmaceuticals announces two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 4, 2022 03:51PM Biotech Acquisition (BIOT) Files Amended S4 for Proposed Merger with Blade Therapeutics
Apr 4, 2022 03:49PM Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
Apr 4, 2022 08:00AM Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
Apr 4, 2022 06:00AM Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
Apr 4, 2022 06:00AM AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals
Mar 31, 2022 06:31AM Nuvalent (NUVL) Appoints Anna Protopapas as Chair of Board of Directors
View More Recent Stories View Older Stories